Announced
Completed
Synopsis
Alto Partners, a private equity firm, completed the acquisition of 40% of Diatech Pharmacogenetics, a developer of pharmacogenetics tests specialized in cancer precision medicine. Diatech, founded in 1998 by Fabio Biondi and headquartered in Jesi is a provider of diagnostic solutions and reagents in the pharmacogenetics and pharmacogenomics sectors. The company provides customized genomic testing solutions in the oncological disease niche, aimed at optimizing cancer treatment effectiveness through increased diagnosis precision.
Show Details & Financials
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.